## **Supporting information**

## Discovery of 5-phenylpyrazolopyrimidinone analogues as potent antitrypanosomal agents with *in vivo* efficacy

Yang Zheng<sup>a,1</sup>, Magali van den Kerkhof<sup>b,1</sup>, Tiffany van der Meer<sup>a</sup>, Sheraz Gul<sup>c,d</sup>, Maria Kuzikov<sup>c,d</sup>, Bernhard Ellinger<sup>c,d</sup>, Iwan J.P. de Esch<sup>a</sup>, Marco Siderius<sup>a</sup>, An Matheeussen<sup>b</sup>, Louis Maes<sup>b</sup>, Geert Jan Sterk<sup>a</sup>, Guy Caljon<sup>b,1\*</sup> and Rob Leurs<sup>a,1\*</sup>

<sup>a</sup> Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, the Netherlands.

<sup>b</sup> Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.

<sup>c</sup> Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 22525 Hamburg, Germany.

<sup>d</sup> Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, 22525 Hamburg, Germany

<sup>1</sup> Authors contributed equally to this manuscript.

\* Corresponding authors: guy.caljon@uantwerpen.be (Guy Caljon); r.leurs@vu.nl (Rob Leurs).

## Table of contents

Figure S1. Structures of approved HAT treatments.	Page S2
Table S1. Physicochemical properties of 1 (BIPPO).	Page S2
Table S2. Phenotypic activity of close BIPPO analogues against T. b. brucei, T. cruzi	
and L. infantum.	Page S3
Figure S2. Antitrypanosomal potency of 23, 30 and 31.	Page S4
Figure S3. Anti- <i>Tbr</i> PDEB1 activity of <b>30</b> .	Page S4
Table S2. Safety profile of analogue <b>30</b> (NPD-2975) from <i>Eurofins</i> .	Page S5
Table S3. In vitro metabolic stability of <b>30</b> using mouse, rat and human S9 microsomal fractions.	Page S6
Table S4. Chemical characterization of final compounds.	Page S7
Table S5. Antitrypanosomal potency of final compounds.	Page S8-9
Figure S4-S142. LCMS, <sup>1</sup> H NMR, <sup>13</sup> C NMR and 2D NMR spectroscopy data.	Page S10-S100



Figure S1. Structures of approved HAT treatments.

Table S1. Physicochemical properties of 1 (BIPPO).

Compound No.	1 (BIPPO)
PPB-Mouse	88.6%
PPB-Human	88.3%
Solubility (mg/L) @pH 2.2	51
Solubility (mg/L) @pH 4.5	50
Solubility (mg/L) @pH 6.8	47
t <sub>0.5</sub> -Mouse (min)	29
Clint (microL/min/mg protein)	48
t <sub>0.5</sub> -Human (min)	>130
Clint (microL/min/mg protein)	<5.3

Cada	D1	T. b. brucei	T. cruzi	L. infantum	MRC-5
Code	K.	pIC <sub>50</sub> <sup>a</sup>	pIC <sub>50</sub> <sup>a</sup>	pIC <sub>50</sub> <sup>a</sup>	pIC <sub>50</sub> <sup>a</sup>
1 (BIPPO)	Bn	$4.5\pm0.2$	< 4.2	< 4.2	< 4.2
<b>9</b> (NPD-2960)	4-PyCH <sub>2</sub>	< 4.2	< 4.2	< 4.2	< 4.2
<b>10</b> (NPD-0434)	C <sub>6</sub> H <sub>5</sub> OCH <sub>2</sub>	< 4.2	< 4.2	< 4.2	< 4.2
11 (NPD-3281)	C <sub>6</sub> H <sub>5</sub> (CH <sub>2</sub> ) <sub>2</sub>	< 4.2	< 4.2	< 4.2	< 4.2
12 (NPD-3380)	Me	< 4.2	< 4.2	< 4.2	< 4.2
13 (NPD-3645)	"Bu	$5.0\pm0.0$	< 4.2	< 4.2	< 4.2
14 (NPD-3379)	<sup>i</sup> Pr	$4.4\pm0.1$	< 4.2	< 4.2	< 4.2
15 (NPD-3200)	Ph	$6.6\pm0.1$	< 4.2	< 4.2	< 4.2
16 (NPD-3488)	4-Py	$5.7\pm0.0$	< 4.2	< 4.2	< 4.2
17 (NPD-2973)	4-thiazole	$4.9\pm0.0$	< 4.2	< 4.2	< 4.2

Table S2. Phenotypic activity of close BIPPO analogues against T. b. brucei, T. cruzi and L. infantum.

<sup>*a*</sup> Mean values of at least two independent experiments.



Figure S2. Antitrypanosomal potency of 15, 25, 26, 30 32 and 37. Representative drug susceptibility curves (mean  $\pm$  standard deviation) of 15 (green), 25 (blue), 26 (brown), 30 (black), 32 (red) and 37 (purple) against *T. brucei* with each biological replicate comprised of at least three technical replicates.



Figure S3. Anti-*Tbr*PDEB1 activity of **30**. Representative dose-response curves (mean  $\pm$  standard error of the mean) of **30** (red) for inhibition of the enzymatic activity of *Tbr*PDEB1 catalytic domain with **NPD-0001** (black) as a reference compound.

		NPD-2975					
DiscoverX Gene	Assav Mode	10 µM					
Symbol	rosuy mouc	% Response					
GPCRs		Replicate 1	Replicate 2	Average			
ADORA2A	Agonist	0.0	1.7	0.9			
ADORA2A	Antagonist	15.7	19.2	17.4			
ADRA1A	Agonist	1.2	1.6	1.4			
ADRA1A	Antagonist	0.1	0.0	0.1			
ADRA2A	Agonist	0.0	0.0	0.0			
ADRA2A	Antagonist	27.1	32.8	30.0			
ADRB1	Agonist	0.3	1.1	0.7			
ADRB1	Antagonist	0.0	0.0	0.0			
ADRB2	Agonist	0.0	0.0	0.0			
ADRB2	Antagonist	0.0	0.0	0.0			
AVPR1A	Agonist	0.0	0.0	0.0			
AVPR1A	Antagonist	0.0	0.0	0.0			
CCKAR	Agonist	0.4	0.0	0.2			
CCKAR	Antagonist	21.3	33.4	27.4			
CHRM1	Agonist	0.0	0.0	0.0			
CHRM1	Antagonist	1.5	0.0	0.7			
CHRM2	Agonist	0.0	0.0	0.0			
CHRM2	Antagonist	32.4	24.9	28.7			
CHRM3	Agonist	0.5	1.8	1.2			
CHRM3	Antagonist	15.1	6.7	10.9			
CNR1	Agonist	0.0	0.0	0.0			
CNR1	Antagonist	8.9	12.4	10.7			
CNR2	Agonist	2.0	10.0	6.0			
CNR2	Antagonist	4.1	3.8	4.0			
DRD1	Agonist	0.0	0.0	0.0			
DRD1	Antagonist	3.5	2.9	3.2			
DRD2S	Agonist	2.5	1.9	2.2			
DRD2S	Antagonist	1.5	3.0	2.3			
EDNRA	Agonist	2.0	1.9	2.0			
EDNRA	Antagonist	38.5	20.0	29.3			
HRH1	Agonist	0.7	2.7	1.7			
HRH1	Antagonist	0.0	6.6	3.3			
HRH2	Agonist	1.2	0.0	0.6			
HRH2	Antagonist	0.0	0.0	0.0			
HTR1A	Agonist	0.0	0.0	0.0			
HTR1A	Antagonist	14.8	28.1	21.5			
HTR1B	Agonist	0.0	0.0	0.0			
HTR1B	Antagonist	9.3	9.6	9.5			
HTR2A	Agonist	0.0	0.0	0.0			
HTR2A	Antagonist	12.3	10.7	11.5			
HTR2B	Agonist	0.0	0.0	0.0			
HTR2B	Antagonist	5.2	21.0	13.1			
OPRD1	Agonist	0.0	0.0	0.0			
OPRD1	Antagonist	13.8	18.5	16.2			
OPRK1	Agonist	0.0	0.0	0.0			
OPRK1	Antagonist	14.8	14.3	14.6			
OPRM1	Agonist	0.0	0.0	0.0			
OPRM1	Antagonist	26.4	33.8	30.1			

		NPD-2975					
DiscoverX Gene	Assav Mode	10 µM					
Symbol	- Body mout	% Response					
No. 1							
Nuclear Hormone	Receptors	Replicate 1	Replicate 2	Average			
AR	Agonist	0.0	0.0	0.0			
AR	Antagonist	11.7	0.0	5.8			
GR	Agonist	0.0	0.0	0.0			
GR	Antagonist	0.0	0.0	0.0			
Transporte	rs	Replicate 1	Replicate 2	Average			
DAT	Blocker	17.2	12.2	14.7			
NET	Blocker	0.0	0.0	0.0			
SERT	Blocker	0.0	0.0	0.0			
Ion Channe	els	Replicate 1	Replicate 2	Average			
CAV1.2	Blocker	0.0	0.0	0.0			
GABAA	Opener	2.3	4.3	3.3			
GABAA	Blocker	0.0	6.3	3.1			
hERG	Blocker	0.0	60.9	30.5			
HTR3A	Opener	0.0	0.0	0.0			
HTR3A	Blocker	7.4	9.1	8.3			
KvLQT1/minK	Opener	2.5	0.7	1.6			
KvLQT1/minK	Blocker	3.4	1.3	2.3			
nAChR(a4/b2)	Opener	1.9	0.0	0.9			
nAChR(a4/b2)	Blocker	40.5	19.7	30.1			
NAV1.5	Blocker	0.0	4.6	2.3			
NMDAR (1A/2B)	Opener	7.0	0.0	3.5			
NMDAR (1A/2B)	Blocker	5.2	0.0	2.6			
Non-Kinase En	zymes	Replicate 1	Replicate 2	Average			
AChE	Inhibitor	0.0	0.0	0.0			
COX1	Inhibitor	8.5	17.0	12.7			
COX2	Inhibitor	0.0	0.0	0.0			
MAOA	Inhibitor	12.6	0.0	6.3			
PDE3A	Inhibitor	0.0	0.0	0.0			
PDE4D2	Inhibitor	79.2	71.7	75.5			
Kinases		Replicate 1	Replicate 2	Average			
INSR	Inhibitor	0.0	0.5	0.3			
LCK	Inhibitor	35.4	46.0	40.7			
ROCK1	Inhibitor	7.7	7.5	7.6			
VEGFR2	Inhibitor	0.0	0.0	0.0			

Table S3. Safety profile of analogue **30** (NPD-2975) from *Eurofins*.

Microsomes	Phase-I/II	Time (min)		<b>30</b> <sup><i>a</i></sup>	Ľ	<b>Diclofenac</b> <sup>a</sup>			
		0		100		10	00		
		15	73	± 2.8	85	±	0.0		
	СҮР450 -	30	55	± 1.8	62	±	7.1		
	NADPH	60	33	± 3.4	49	±	2.4		
N			(1	n=2)		(n=	=2)		
Mouse _		0		100		10	00		
		15	93	± 4.2	56	±	16		
	UGT enzymes	30	81	± 2.7	46	±	10		
		60	71	± 5.4	39	±	0.0		
			(1	n=2)		(n=2)			
		0			100				
	CN/D450	15	93	± 10.2	73	±	15.1		
	СҮР450 -	30	92	± 2.4	57	±	24.0		
	NADPH	60	78	± 0.2	34	±	36.5		
Pat			(1	n=2)		(n=	=3)		
Kat _		0		100		100			
		15	84	± 4.9	42	±	21.8		
	UGT enzymes	30	87	± 3.6	27	±	23.2		
		60	76	± 7.1	22	±	17.9		
			(1	n=2)		(n=	=3)		
		0		100		10	00		
	CVP450 -	15	102	± 5.3	43	±	3.5		
	NADPH	30	99	± 3.1	14	±	1.4		
		60	92	± 3.1	3	±	0.0		
Human -			(1	n=3)		(n=	=2)		
		0		100		10	00		
	LOT	15	81	± 1.1	21	±	0.7		
	UGT enzymes	30 60	79 75	$\pm 2.9$ $\pm 2.2$	14	± +	1.4 0.7		
		00	(1	– ∠.∠ n=4)	11	 (n=	=2)		

Table S4. In vitro metabolic stability of 30 using mouse, rat and human S9 microsomal fractions.

<sup>a</sup> Results are based on at least two repeats and are expressed as mean percentage remaining  $30 \pm$  standard error of mean (SEM).



Code	$\mathbb{R}^1$	Formula	Yields from <b>8</b>	LCMS retention time	LCMS purity at	HR-MS	$[M+H]^{+}$
				(min)	254 nm	Calculated	Found
1	Bn	$C_{15}H_{16}N_4O$	68%	3.66	>99%	269.1397	269.1385
9	4-PyCH <sub>2</sub>	$C_{14}H_{15}N_5O$	59%	2.26	98%	270.1349	270.1341
10	C <sub>6</sub> H <sub>5</sub> OCH <sub>2</sub>	$C_{15}H_{16}N_4O_2$	60%	3.80	>99%	285.1346	285.1341
11	$C_6H_5(CH_2)_2$	$C_{16}H_{18}N_4O$	71%	3.87	>99%	283.1553	283.1545
12	Me	$C_9H_{12}N_4O$	90%	2.46	>99%	193.1084	193.1090
13	<sup>n</sup> Bu	$C_{12}H_{18}N_4O$	42%	3.58	>99%	235.1553	235.1562
14	<sup>i</sup> Pr	$C_{11}H_{16}N_4O$	87%	3.42	>99%	221.1397	221.1405
15	Ph	$C_{14}H_{14}N_4O$	32%	3.78	>99%	$277.1060^{a}$	$277.1070^{a}$
16	4-Py	$C_{13}H_{13}N_5O$	33%	2.63	>99%	256.1193	256.1186
17	4-thiazole	$C_{11}H_{11}N_5OS$	54%	3.40	>99%	262.0757	262.0756
18	2-F-Ph	$C_{14}H_{13}FN_4O$	33%	3.66	>99%	273.1146	273.1144
19	2-Cl-Ph	C <sub>14</sub> H <sub>13</sub> ClN <sub>4</sub> O	56%	3.66	>99%	289.0851	289.0850
20	2-Br-Ph	C14H13BrN4O	88%	3.69	>99%	333.0346	333.0333
21	2-Me-Ph	$C_{15}H_{16}N_4O$	43%	3.79	>99%	269.1397	269.1405
22	2-OMe-Ph	$C_{15}H_{16}N_4O_2$	5%	3.96	>99%	285.1346	285.1333
23	3-F-Ph	C <sub>14</sub> H <sub>13</sub> FN <sub>4</sub> O	37%	3.98	98%	295.0966 <sup>a</sup>	295.0954 <sup>a</sup>
24	3-Cl-Ph	C <sub>14</sub> H <sub>13</sub> ClN <sub>4</sub> O	4%	4.25	99%	311.0670 <sup>a</sup>	311.0676 <sup>a</sup>
25	3-Me-Ph	C15H16N4O	63%	4.10	>99%	269.1397	269.1386
26	3-OMe-Ph	$C_{15}H_{16}N_4O_2$	33%	3.87	>99%	285.1346	285.1339
27	3-OH-Ph	$C_{14}H_{14}N_4O_2$	41%	3.23	>99%	271.1190	271.1185
28	3-N(CH <sub>3</sub> ) <sub>2</sub> -Ph	C <sub>16</sub> H <sub>19</sub> N <sub>5</sub> O	45%	3.71	>99%	298.1662	298.1662
29	3-SO <sub>2</sub> CH <sub>3</sub> -Ph	$C_{15}H_{16}N_4O_3S$	24%	3.29	95%	333.1016	333.1012
30	4-F-Ph	C <sub>14</sub> H <sub>13</sub> FN <sub>4</sub> O	62%	3.89	>99%	273.1146	273.1144
31	4-Cl-Ph	C <sub>14</sub> H <sub>13</sub> ClN <sub>4</sub> O	37%	4.32	98%	289.0851	289.0839
32	4-Br-Ph	C <sub>14</sub> H <sub>13</sub> BrN <sub>4</sub> O	54%	4.38	>99%	333.0346	333.0347
33	4-OMe-Ph	$C_{15}H_{16}N_4O_2$	58%	3.86	>99%	285.1346	285.1343
34	4-O <sup>i</sup> Pr-Ph	$C_{17}H_{20}N_4O_2$	36%	4.40	>99%	313.1659	313.1651
35	4-CF <sub>3</sub> -Ph	C <sub>15</sub> H <sub>13</sub> F <sub>3</sub> N <sub>4</sub> O	42%	4.43	>99%	345.0934 <sup>a</sup>	345.0920 <sup>a</sup>
36	4-OCF <sub>3</sub> -Ph	$C_{15}H_{13}F_{3}N_{4}O_{2}$	15%	4.54	>99%	339.1063	339.1069
37	4-CN-Ph	$C_{15}H_{13}N_5O$	37%	3.69	>99%	280.1193	280.1182
38	4-COOMe-Ph	$C_{16}H_{16}N_4O_3$	34%	3.83	97%	313.1295	313.1284
39	4-COOH-Ph	$C_{15}H_{14}N_4O_3$	26%	3.16	99%	299.1139	299.1101
40	4-CONH2-Ph	$C_{15}H_{15}N_5O_2$	18%	2.76	97%	320.1118 <sup>a</sup>	320.1105 <sup>a</sup>
41	4-SO <sub>2</sub> Me-Ph	C15H16N4O3S	30%	3.27	97%	333.1016	333.1011
42	4-SO <sub>2</sub> NH <sub>2</sub> -Ph	C14H15N5O3S	19%	2.96	>99%	334.0969	334.0953
43	4-NHCOCH <sub>3</sub> -Ph	$C_{16}H_{17}N_5O_2$	47%	3.06	>99%	312.1455	312.1443
44	4-(N-piperidine)-Ph	$C_{19}H_{23}N_5O$	23%	4.34	>99%	338.1975	338.1964
45	4-( <i>N</i> -methylpipera-	$C_{19}H_{24}N_6O$	35%	2.53	98%	353.2084	353.2078
46	4-tetrazole-Ph	$C_{15}H_{14}N_8O$	26%	3.10	>99%	323.1363	323.1357
a 53 6 · 33							

 $a: [M+Na]^+.$ 

Screening concentration (µM)						IC.	IC					
Code	64	16	4	1	0.25	0.06	0.016	0.004	0.001	0.0002	10.50	10.90
	0		_		Gro	wth inl	hibition (	(%)				μM
9 (NPD-2960)	9	15	7	11	7						> 64.0	> 64.0
9 (NPD-2960)	) 15	8	/	/	0						> 64.0	> 64.0
10 (NPD-0434)	15	5	I	0	0						> 64.0	> 64.0
10 (NPD-0434)	20	5	0	0	0						> 64.0	> 64.0
11 (NPD-3281)	30	12	14	11	15						> 64.0	> 64.0
11 (NPD-3281)	50	39	9	3	11						64.0	> 64.0
12 (NPD-3380)	0	0	0	0	0						> 64.0	> 64.0
12 (NPD-3380)	9		2	ſ	2	2	0				> 64.0	> 64.0
<b>13</b> (NPD-3645)	/5 72	6/	22	6	3	2	8				9.5	> 64.0
<b>13</b> (NPD-3645)	12	05	27	0	0	0	0				9.3	> 64.0
14 (NPD-3379)	66	23	0	0	0						38.2	> 64.0
14 (NPD-33/9)	60	1/	8	10	50						46.4	> 64.0
15 (NPD-3200)	80 70	84	84 70	84	50 20						0.3	N.D.
15 (NPD-3200)	/ 8	80	/9	/0	39 70	10	4	0	0	C	0.4	N.D.
15 (NPD-3200)	89	8/	93	93	12	19	4	0	0	2	0.14	0.82
15 (NPD-3200)	91	94	97	90	85	11	2	1	4	4	0.13	0.4/
16 (NPD-3488)	85	85	69 75	27	8	0	10				2.1	> 64.0
10 (NPD-3488) 17 (NDD 2072)	82 80	80 54	/3	21	21	9	12				1.8	> 64.0
17 (NPD-2973) 17 (NDD 2072)	80	54 59	10	3	3						14.1	> 64.0
17 (NPD-29/3) 19 (NDD 2100)	82 95	28 95	) 04	50	0						13.0	> 64.0
18 (NPD-3199) 18 (NDD-2100)	85	85	84 70	28 49	11 5						0.8	> 64.0
10 (NPD - 3199)	77	80	79	48	5	21	0				1.1	> 64.0
19 (NPD-3538)	12	/1	12	48	0	21	0				1.1	> 64.0
19 (NPD-3538)	71	78	78	70	28	10	3				0.5	> 64.0
20 (NPD-3539)	/1	70	13	20	18	19	1				0.8	> 64.0
20 (NPD-3339)	13	//	/0	00	20	5	15				0.0	> 04.0
21 (NPD-3389) 21 (NDD 2580)	03 70	90 77	01 70	01 70	33 73	20	/				0.2	10.0
21 (NPD - 3509)	/0 01	76	21	2	12	20	5				6.8	> 64.0
22 (NID-3590)	77	66	20	0	0	0	0				0.0	> 64.0
22 (NID-3390) 23 (NDD 3202)	87	86	29 85	86	75	0	0				< 0.3	> 64.0
$23 (NPD_{-3202})$	07 81	81	80	80	63						< 0.3	> 64.0
<b>23</b> (NPD-3202)	80	79	79	79	03 74	30	0				0.1	> 64.0
<b>23</b> (NPD-3202)	86	85	85	84	80	35	0				0.1	> 64.0
23 (NPD-3591)	80	81	78	79	50	14	7				0.1	> 64.0
24 (NPD-3591)	81	79	78	76	70	29	6				0.5	> 64.0
25 (NPD-3382)	85	84	84	79	37	2)	0				0.1	N D
25 (NPD-3382)	82	82	82	79	43						0.1	ND
25 (NPD-3382)	90	91	91	89	62	24	7	0	0	0	0.16	2.0
25 (NPD-3382)	92	93	94	94	70	12	3	5	7	11	0.16	0.79
<b>26</b> (NPD-3375)	92	85	82	66	28	12	5	5	,	11	0.10	N D
<b>26</b> (NPD-3375)	91	91	81	62	39						0.5	N D
26 (NPD-3375)	95	89	88	70	24	4	3	4	0	0	0.55	20.16
<b>26</b> (NPD-3375)	97	91	91	75	30	5	4	5	8	13	0.55	3 67
<b>27</b> (NPD-2974)	80	72	34	6	3	-	•	5	0	10	7.2	> 64.0
<b>27</b> (NPD-2974)	81	77	37	6	0						6.3	> 64.0
<b>28</b> (NPD-3381)	87	72	20	Ő	õ						8.9	> 64.0
<b>28</b> (NPD-3381)	84	70	$\frac{1}{26}$	Ő	ő						8.5	> 64.0
<b>29</b> (NPD-3598)	79	24	4	Ő	7	0	2				30.8	> 64.0
<b>30</b> (NPD-2975)	81	76	76	76	, 76	0	-				< 0.3	N.D.
<b>30</b> (NPD-2975)	83	81	84	82	79						< 0.3	N.D.
<b>30</b> (NPD-2975)	85	84	84	84	82	45	33				0.1	N.D.

Table S6. Anti-*T.brucei* potency of final compounds.

<b>30</b> (NPD-2975)	84	85	84	85	82	39	11				0.1	N.D.
<b>30</b> (NPD-2975)	90	90	91	93	96	69	10	3	2	0	0.04	0.18
<b>30</b> (NPD-2975)	91	93	93	94	96	65	7	8	11	11	0.04	0.19
31 (NPD-3204)	90	89	87	85	83						< 0.3	64.0
31 (NPD-3204)	85	85	81	81	71						< 0.3	> 64.0
31 (NPD-3204)	82	83	81	81	74	39	3				0.1	> 64.0
31 (NPD-3204)	89	89	87	84	81	36	0				0.1	> 64.0
32 (NPD-2971)	81	78	76	67	28						0.5	N.D.
32 (NPD-2971)	85	83	84	78	30						0.4	N.D.
32 (NPD-2971)	92	92	93	91	73	18	6	3	0	3	0.14	0.93
32 (NPD-2971)	93	94	94	91	64	9	4	9	10	11	0.18	0.95
33 (NPD-2972)	83	79	74	52	10						0.9	> 64.0
33 (NPD-2972)	85	83	82	59	18						0.7	> 64.0
<b>34</b> (NPD-3377)	47	42	34	2	0						> 64.0	> 64.0
<b>34</b> (NPD-3377)	61	52	34	10	11						13.7	> 64.0
35 (NPD-3201)	93	87	84	46	10						1.2	32.0
35 (NPD-3201)	91	83	79	42	0						1.3	53.8
<b>36</b> (NPD-3597)	95	83	70	42	6	2	2				1.5	35.9
<b>36</b> (NPD-3597)	81	78	73	52	32	6	8				0.9	> 64.0
<b>37</b> (NPD-3203)	89	88	86	84	46						0.3	N.D.
<b>37</b> (NPD-3203)	83	81	75	72	33						0.5	N.D.
<b>37</b> (NPD-3203)	95	94	94	96	72	35	7	3	0	0	0.11	0.71
<b>37</b> (NPD-3203)	92	93	94	92	49	7	3	4	7	9	0.26	0.94
<b>38</b> (NPD-3305)	48	9	6	5	2						> 64.0	> 64.0
<b>38</b> (NPD-3305)	43	10	2	5	0						> 64.0	> 64.0
<b>39</b> (NPD-3489)	4	3	0	0	0						> 64.0	> 64.0
<b>40</b> (NPD-3371)	5	2	0	0	0						> 64.0	> 64.0
<b>40</b> (NPD-3371)	4	7	0	5	5						> 64.0	> 64.0
<b>41</b> (NPD-3376)	52	22	1	0	0						58.4	> 64.0
<b>41</b> (NPD-3376)	62	16	15	5	14						44.6	> 64.0
<b>42</b> (NPD-3372)	70	26	5	0	0						34.1	> 64.0
<b>42</b> (NPD-3372)	64	20	6	6	0						41.2	> 64.0
<b>43</b> (NPD-3280)	12	11	11	12	15						> 64.0	> 64.0
<b>43</b> (NPD-3280)	13	26	13	14	4						> 64.0	> 64.0
44 (NPD-3283)	38	35	29	20	20						> 64.0	> 64.0
44 (NPD-3283)	83	48	28	32	8						17.3	> 64.0
45 (NPD-3282)	50	26	13	10	15						64.0	> 64.0
45 (NPD-3282)	97	87	11	12	7						8.1	24.3
46 (NPD-3490)	23	16	1	3	3						> 64.0	> 64.0

N.D.: not determined.







MS Spectrum Table

Figure S4. LCMS spectrum of intermediate 4.



Figure S6. <sup>13</sup>C NMR spectrum of intermediate **4**.







Figure S7. LCMS spectrum of intermediate 5.



Figure S9. <sup>13</sup>C NMR spectrum of compound 5.







Figure S10. LCMS spectrum of compound intermediate 6.



Figure S12. <sup>13</sup>C NMR spectrum of compound intermediate 6.







9988

Figure S13. LCMS spectrum of compound intermediate 7.

22731

67

221.10

1.14 8.98



Figure S15. <sup>13</sup>C NMR spectrum of compound intermediate 7.



Figure S16. LCMS spectrum of compound 8.







Figure S18. <sup>13</sup>C NMR spectrum of intermediate 8.





2	7.474	24230	0.204



Figure S19. LCMS spectrum of compound 1 (NPD-0019).



Figure S21. <sup>13</sup>C NMR spectrum of compound **1** (NPD-0019).



Figure S22. LCMS spectrum of compound 9 (NPD-2960).





Figure S24. <sup>13</sup>C NMR spectrum of compound 9 (NPD-2960).



Figure S25. LCMS spectrum of compound 10 (NPD-0434).



Figure S27. <sup>13</sup>C NMR spectrum of compound **10** (NPD-0434).







Figure S28. LCMS spectrum of compound 11 (NPD-3281).



Figure S30. <sup>13</sup>C NMR spectrum of compound **11** (NPD-3281).





MS Spectrum Table

	Mis specifium Table												
#:1 Ref	t.Time:					1.07940.000.500.500							
BG Mode:Calc 2.410<->2.790(242<->280)													
Mass Pe	Mass Peaks: 9 Base Peak: 193.05(675266) Polarity:Pos Segment1 - Event1												
#	m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs.Inten.	Rel.Inten.	Charge	Pol arity	Monoisotopic
1	193.05	675266	100.00				6	256.05	24769	3.67			
2	194.05	65587	9.71				7	385.05	9084	1.35			
3	215.00	32079	4.75				8	407.15	55292	8.19			
4	231.00	8680	1.29				9	408.15	15853	2.35			
5	234.05	16383	2.43										

Figure S31. LCMS spectrum of compound 12 (NPD-3380).



Figure S33. <sup>13</sup>C NMR spectrum of compound **12** (NPD-3380).



Figure S34. LCMS spectrum of compound 13 (NPD-3645).



Figure S36. <sup>13</sup>C NMR spectrum of compound **13** (NPD-3645).







Figure S37. LCMS spectrum of compound 14 (NPD-3379).



Figure S39. <sup>13</sup>C NMR spectrum of compound 14 (NPD-3379).







#:1 Ret Time: BG Mode Calc 3.700<->4.090(371<->410) Mass Peaks:13 Base Peak:255.10(772560) Polarity:Pos Segment1 - Event1 m/z 255.10 256.10 257.10 277.10 278.10 m/z 297.15 318.10 319.10 528.50 531.30 532.30 Abs. Inten. 772560 125886 Rel.Inten. Charge Polarity 100.00 Abs.Inten. 16084 80834 # Monoisotopic # Rel.Inten. Charge Polarity Monoisotopic 2.08 10.46 2.05 1.02 8.30 3.11 1 8 9 16.00 16.29 1.33 8.59 1.26 1.55 9.97 2 10 11 12 13 15800 7861 64127 3 10257 66368 9738 11959 4 5 6 7 293.00 24020 296.10 76995

Figure S40. LCMS spectrum of compound 15 (NPD-3200).



Figure S42. <sup>13</sup>C NMR spectrum of compound 15 (NPD-3200).







Figure S43. LCMS spectrum of compound 16 (NPD-3488).


Figure S45. <sup>13</sup>C NMR spectrum of compound 16 (NPD-3488).







Figure S46. LCMS spectrum of compound 17 (NPD-2973).



Figure S48. <sup>13</sup>C NMR spectrum of compound 17 (NPD-2973).



Figure S49. LCMS spectrum of compound 18 (NPD-3199).



Figure S51. <sup>13</sup>C NMR spectrum of compound **18** (NPD-3199).







#1 Re	t.Time:					MS Spe	ctrum Table						
BG Mo	de: Calc 3.57)	0<->4.070(35	8<->408)										
Mass Pe	aks:16 Bas	e Peak:289.0	5(1524922)	Polarity	Pos Segn	nenti - Eventi							
#	m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic
1	289.05	1524922	100.00	24.19 Million = 1.94	0000000000	11.1020331.010.003010.01 <del>.0</del> .0190	9	331.05	16309	1.07		(2004, SP (12), SR • )	1999-990-990-990-990-990-
2	290.05	260433	17.08				10	332.10	25098	1.65			
3	291.00	481508	31.58				11	352.05	119175	7.82			
4	292.00	75350	4.94				12	353.05	21959	1.44			
5	311.00	90213	5.92				13	354.10	42185	2.77			
б	312.05	15563	1.02				14	599.15	58059	3.81			
7	313.05	36115	2.37				15	600.15	22825	1.50			
8	330.05	75293	4.94				16	601.15	46128	3.02			

Figure S52. LCMS spectrum of compound 19 (NPD-3538).



Figure S54. <sup>13</sup>C NMR spectrum of compound **19** (NPD-3538).







18710

357.00

Figure S55. LCMS spectrum of compound 20 (NPD-3539).

15.03

42171

3

4

336.00



Figure S57. <sup>13</sup>C NMR spectrum of compound **20** (NPD-3539).







MS Spectrum Table

BG M	ode: Calc 3.72	0<->4.200(31	73<->421)										
Mass	Peaks:10 Bas	e Peak:269.0	5(2106094)	Polarity	Pos Segm	nent1 - Event1							
#	m/z	Abs. Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs. Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic
1	269.05	2106094	100.00				6	310.05	36373	1.73			
2	270.05	377771	17.94				7	332.10	151953	7.21			
3	271.05	35728	1.70				8	333.10	30653	1.46			
4	291.05	138338	6.57				9	559.25	70066	3.33			
5	307.05	23669	1.12				10	560.20	23844	1.13			

Figure. S58 LCMS spectrum of compound 21 (NPD-3589).

#1 Ret.Time:



Figure S60. <sup>13</sup>C NMR spectrum of compound **21** (NPD-3589).







ΜS	Spectrum	Table
----	----------	-------

					THE PARTY OF THE PARTY.							
t.Time:												
ie: Calc 3.92	0<->4.320(39	93<->433)										
aks:11 Bas	e Peak:285.1	0(1408931)	Polarity	Pos Segn	nent1 - Event1							
m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic
285.10	1408931	100.00				7	326.15	18220	1.29			
286.10	292161	20.74				8	348.05	86367	6.13			
287.05	27635	1.96				9	349.05	17684	1.26			
307.05	139653	9.91				10	591.20	105593	7.49			
308.10	18033	1.28				11	592.20	36837	2.61			
323.05	14162	1.01										
	Time: le: Calc 3.92 aks:11 Bas m/z 285.10 286.10 287.05 307.05 308.10 323.05	.Time: le Calo 3.920 <->4.320(3) aks:11 Base Peak:285.1 m/z Abs.Inten. 285.10 1408931 286.10 292161 287.05 27635 307.05 139653 308.10 18033 323.05 14162	.Time: le: Calc 390 <->4 320(393 <->433) aks:11 Base Peak: 285.10(1408931) m/z Abs.Inten Rel.Inten. 285.10 1408931 100.00 286.10 292161 20.74 287.05 27635 1.96 307.05 139653 9.91 308.10 139633 9.91 308.10 14033 1.28	.Time: le: Calc 390 <->4.320(393 <->433) aks:11 Base Peak: 285.10(1408931) Polanty m/z Abs.Inten. Rel.Inten. Charge 285.10 1408931 100.00 286.10 292161 20.74 287.05 27635 1.96 307.05 139653 9.91 308.10 139633 9.91 302.15 14162 1.01	Time:	Time: le Calc 390 <->4.320(393 <->433) aks:11 Base Peak: 285.10(1408931) Polarity:Pos Segment1 - Event1 m/z Abs.Inten. Rel.Inten. Charge Polarity Monoisotopic 285.10 1408931 100.00 286.10 292161 20.74 287.05 27635 1.96 307.05 139653 9.91 308.10 18033 1.28 323.05 14162 1.01	Time:  Time:    le: Calc 3, 920 <->4,320(393 <->433)    aks:11  Base Peak: 285,10(1408931)    polarity:Pos Segment1 - Event1    m/z  Abs.Inten    Rel.Inten.  Charge Polarity    285,10  1408931    286,10  292161    20,74  8    287,05  27635    1,96  9    307,05  139653    1,03  1,28    11  323,05    323,05  14162	Time: le Calc 3294 <>4.320(393 <>433) aks:11 Base Peak:285.10(1408931) Polarity:Pos Segment1 - Event1 m/z Abs.Inten. Rel.Inten. Charge Polarity Monoisotopic # m/z 285.10 1408931 100.00 7 326.15 286.10 292161 20.74 8 348.05 287.05 27635 1.96 9 349.05 307.05 139653 9.91 10 591.20 308.10 18033 1.28 11 592.20 323.05 14162 1.01	Time: le Calc 3, 920 <> 4, 320 (393 <> 433) aks:11 Base Peak: 285, 10(1408931) Polarity.Pos Segment1 - Event1 m/z Abs.Inten. Rel.Inten. Charge Polarity Monoisotopic # m/z Abs.Inten. 285,10 1408931 100,00 7 326,15 18220 286,10 292161 20.74 8 348,05 86367 287,05 27635 1.96 9 349,05 17684 307,05 139653 9.91 10 591,20 105593 308,10 18033 1.28 11 592,20 36837 323,05 14162 1.01	Time: le Calc 320 <>4.320(393 <>>433) aks:11 Base Peak:285.10(1408931) Polarity:Pos Segment1 - Event1 m/z Abs.Inten. Rel.Inten. Charge Polarity Monoisotopic # m/z Abs.Inten. Rel.Inten. 285.10 1408931 100.00 7 326.15 18220 1.29 286.10 292161 20.74 8 348.05 86367 6.13 287.05 27635 1.96 9 349.05 17684 1.26 307.05 139653 9.91 10 591.20 105593 7.49 308.10 18033 1.28 11 592.20 36837 2.61 323.05 14162 1.01	Time: le Calc 3292<->4.320(393<->433) aks:11 Base Peak:285.10(1408931) Polarity:Pos Segment1 - Event1 m/z Abs.Inten. Rel.Inten. Charge Polarity Monoisotopic # m/z Abs.Inten. Rel.Inten. Charge 285.10 1408931 100.00 7 326.15 18220 1.29 286.10 292161 20.74 8 348.05 86367 6.13 287.05 27635 1.96 9 349.05 17684 1.26 307.05 139653 9.91 10 591.20 105593 7.49 308.10 18033 1.28 11 592.20 36837 2.61	Time: le Calc 3.920 <>4.320(393 <>>433) aks:11 Base Peak:285.10(1408931) Polarity:Pos Segment1 - Event1 m/z Abs.Inten. Rel.Inten. Charge Polarity Monoisotopic # m/z Abs.Inten. Rel.Inten. Charge Polarity 285.10 1408931 100.00 7 326.15 18220 1.29 286.10 292161 20.74 8 348.05 86367 6.13 287.05 27635 1.96 9 349.05 17684 1.26 307.05 139653 9.91 10 591.20 105593 7.49 308.10 18033 1.28 11 592.20 36837 2.61

Figure S61. LCMS spectrum of compound 22 (NPD-3590).



Figure S63. <sup>13</sup>C NMR spectrum of compound 22 (NPD-3590).



Figure S64. LCMS spectrum of compound 23 (NPD-3202).



Figure S66. <sup>13</sup>C NMR spectrum of compound 23 (NPD-3202).







MS Spectrum Graph



						MS Spe	ctrum Table						
#:1 Re	t.Time:					67979-000 <del>-</del> 201							
BG Mo	de:Calc 4.19	0<->4.490(42	0<->450)										
Mass Pe	eaks:18 Bas	e Peak:289.0:	5(269467)	Polarity: I	Pos Segme	ent1 - Event1							
#	m/z	Abs. Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs. Inten.	Rel.Inten.	Charge	Pol arity	Monoisotopic
1	289.05	269467	100.00	-	-	_	10	331.10	10065	3.74	-		_
2	290.00	49867	18.51				11	332.10	18171	6.74			
3	291.10	79825	29.62				12	333.10	4125	1.53			
4	292.10	14178	5.26				13	352.10	37789	14.02			
5	311.05	17517	6.50				14	353.25	5742	2.13			
6	313.05	5487	2.04				15	354.05	12482	4.63			
7	327.10	5969	2.22				16	605.15	5778	2.14			
8	329.25	2972	1.10				17	606.00	7511	2.79			
9	330.10	55307	20.52				18	606.95	3608	1.34			

Figure S67. LCMS spectrum of compound 24 (NPD-3591).



Figure S69. <sup>13</sup>C NMR spectrum of compound **24** (NPD-3591).







Figure S70. LCMS spectrum of compound 25 (NPD-3382).



Figure S72. <sup>13</sup>C NMR spectrum of compound **25** (NPD-3382).







Figure S73. LCMS spectrum of compound 26 (NPD-3375).



Figure S75. <sup>13</sup>C NMR spectrum of compound **26** (NPD-3375).



#:1 Ret	Time:												
BG Mod	le:Calc 3.20	0<->3.440(32	1<->345)										
Mass Pe	aks:10 Bas	se Peak:271.0	5(170873)	Polarity: H	Pos Segme	ntl - Eventl							
#	m/z	Abs. Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs. Inten.	Rel.Inten.	Charge	Pol arity	Monoisotopic
1	271.05	170873	100.00				6	309.05	5301	3.10			
2	272.00	28445	16.65				7	334.00	9979	5.84			
3	273.10	2799	1.64				8	335.00	2379	1.39			
4	293.05	15035	8.80				9	563.20	18408	10.77			
5	294.10	3082	1.80				10	564.25	7953	4.65			

Figure S76. LCMS spectrum of compound 27 (NPD-2974).



Figure S78. <sup>13</sup>C NMR spectrum of compound 27 (NPD-2974).



Figure S79. LCMS spectrum of compound 28 (NPD-3381).



Figure S81. <sup>13</sup>C NMR spectrum of compound **28** (NPD-3381).



Figure S82. LCMS spectrum of compound 29 (NPD-3598).



Figure S84. <sup>13</sup>C NMR spectrum of compound **29** (NPD-3598).







Figure S85. LCMS spectrum of compound 30 (NPD-2975).



Figure S87. <sup>13</sup>C NMR spectrum of compound **30** (NPD-2975).



Figure S89. HMBC spectrum of compound **30** (NPD-2975).



Figure S91. <sup>13</sup>C NMR spectrum of **30**·xHCl.



Figure S93. HMBC spectrum of **30**·xHCl.



Figure S94. 1,n-ADEQUATE spectrum of 30·xHCl.

Acquired by Date Acquired	: Admin - 3/7/2019 12-38-00 PM
Sample Name	: VUF16258
Sample ID	
Tray#	:1
Vial#	: 16
Injection Volume	: 3
Data File	: C:\LabSolutions\Data\2019\2019-wk27\VUF16258.lcd
Background File	: blanco 03072019.1cd
Method File	: Method SCAN ACID standard.lcm
Report Format	: DefaultLCMS.lcr
Tuning File	: C:\LabSolutions\Tuning\Tuning-ESI-pos-neg01072015alct
Processed by	Admin
Modified Date	: 3/7/2019 1:00:26 PM



PDACh1 2	54nm 4nm			
Peak#	Name	Ret. Time	Area	Area %
1		3.612	49161	0.290
2		3.851	136099	0.803
3		4.172	80388	0.474
4		4.320	16651820	98.220
5		4.879	36047	0.213



## MS Spectrum Table

						MID DPC	caronin r dore						
#1 Ref	t.Time:					1.54							
BG Moo	de: Calc 4.27	0<->5.010(42	28<->502)										
Mass Pe	eaks:20 Bas	e Peak:289.0	5(1855458)	Polarity	Pos Segn	nent1 - Event1							
#	m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs.Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic
1	289.05	1855458	100.00		0000000000	11.1020431.2010.000440.01 <del>.2</del> .2010	11	332.05	49527	2.67		(2017-08-00-06C=)	1999-2010 - 1999-2010 - 1992
2	290.00	382010	20.59				12	334.10	21179	1.14			
3	291.00	631041	34.01				13	352.00	198202	10.68			
4	292.00	97642	5.26				14	353.00	37343	2.01			
5	311.00	106208	5.72				15	354.05	64047	3.45			
6	312.05	20916	1.13				16	483.20	65350	3.52			
7	313.00	38894	2.10				17	485.15	23119	1.25			
8	327.00	24731	1.33				18	505.15	44990	2.42			
9	330.00	141151	7.61				19	599.15	61199	3.30			
10	331.00	29256	1.58				20	601.15	33455	1.80			

Figure S95. LCMS spectrum of compound **31** (NPD-3204).

PeakTabl



Figure S97. <sup>13</sup>C NMR spectrum of compound **31** (NPD-3204).





Figure S98. LCMS spectrum of compound 32 (NPD-2971).


Figure S100. <sup>13</sup>C NMR spectrum of compound **32** (NPD-2971).





Figure S101. LCMS spectrum of compound 33 (NPD-2972).



Figure S103. <sup>13</sup>C NMR spectrum of compound **33** (NPD-2972).

Admin
: 25/4/2018 1:58:14 PM
: YAZH01-201
: 1
: 21
: 3
: C:\LabSolutions\Data\2018\2018-wk17\YAZH01-201.lcd
: blanco 25042018.lcd
: Method SCAN ACID standard.lcm
: DefaultLCMS.lcr
: C:\LabSolutions\Tuning\Tuning-ESI-pos-neg01072015alct
Admin
: 25/4/2018 2:09:39 PM





Figure S104. LCMS spectrum of compound 34 (NPD-3377).



Figure S106. <sup>13</sup>C NMR spectrum of compound 34 (NPD-3377).





Figure S107. LCMS spectrum of compound 35 (NPD-3201).



Figure S109. <sup>13</sup>C NMR spectrum of compound **35** (NPD-3201).





Peak#	Name	Ret. Time	Area	Area%
1		4.077	30020	0.658
2		4.540	4534064	99.342



Figure S110. LCMS spectrum of compound 36 (NPD-3597).



Figure S112. <sup>13</sup>C NMR spectrum of compound **36** (NPD-3597).







Figure S113. LCMS spectrum of compound 37 (NPD-3203).



Figure S114. <sup>1</sup>H NMR spectrum of compound **37** (NPD-3203).



Figure S115. <sup>13</sup>C NMR spectrum of compound **37** (NPD-3203).



Figure S116. LCMS spectrum of compound 38 (NPD-3305).



Figure S118. <sup>13</sup>C NMR spectrum of compound **38** (NPD-3305).







Figure S119. LCMS spectrum of compound 39 (NPD-3489).



Figure S121. <sup>13</sup>C NMR spectrum of compound **39** (NPD-3489).







Figure S122. LCMS spectrum of compound 40 (NPD-3371).



Figure S124. <sup>13</sup>C NMR spectrum of compound **40** (NPD-3371).









Figure S125. LCMS spectrum of compound 41 (NPD-3376).

(x100,000) 1.70 175,940 1.00

0.00

TIC@1



Figure S127. <sup>13</sup>C NMR spectrum of compound 41 (NPD-3376).







Figure S128. LCMS spectrum of compound 42 (NPD-3372).



Figure S130. <sup>13</sup>C NMR spectrum of compound **42** (NPD-3372).







Figure S131. LCMS spectrum of compound 43 (NPD-3280).



Figure S133. <sup>13</sup>C NMR spectrum of compound 43 (NPD-3280).



MS Spectrum Table

m/z

#:1 Re	t.Time:												
BG Mode: Calc 4.250<->4.780(426<->479)													
Mass Peaks:8 Base Peak: 338.10(2315029) Polarity:Pos Segment1 - Event1													
#	m/z	Abs. Inten.	Rel.Inten.	Charge	Polarity	Monoisotopic	#	m/z	Abs. Inten.	Rel.Inten.	Charge	Pol arity	Monoisotopic
1	338.10	2315029	100.00				5	379.15	26705	1.15			
2	339.15	558399	24.12				6	401.15	51029	2.20			
3	340.15	69830	3.02				7	697.40	39606	1.71			
4	360.05	44771	1.93				8	702.95	24657	1.07			

Figure S134. LCMS spectrum of compound 44 (NPD-3283).



Figure S136. <sup>13</sup>C NMR spectrum of compound 44 (NPD-3283).



Figure S137. LCMS spectrum of compound 45 (NPD-3282).



Figure S139. <sup>13</sup>C NMR spectrum of compound 45 (NPD-3282).







Figure S140. LCMS spectrum of compound 46 (NPD-3490).



Figure S142. <sup>13</sup>C NMR spectrum of compound 46 (NPD-3490).